FILE PHOTO: The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California (Reuters) - Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS ...

Jounce Therapeutics is cashing out. Despite having more than $150 million in the bank, the struggling biotech has decided it lacks the means to advance its clinical candidates, leading it to lay off ...

Only two weeks after crashing Redx Pharma’s planned reverse merger into Jounce Therapeutics, Concentra Biosciences’ unsubtle tactics appear to have paid off as it walks home with Jounce. Until a few ...

It ain’t over ‘til it’s over and for Redx Pharma, it’s over. Redx and Jounce Therapeutics announced Monday morning that the two companies agreed to terminate their proposed business combination ...

All-Inclusive TV agency Marketing Architects announces a partnership with Jounce Media to bring greater transparency to Connected TV (CTV) media buying through Marketing Architects' proprietary ...

There’s significant change on the way at Jounce Therapeutics. The embattled clinical-stage company announced Wednesday afternoon that it is laying off more than half of its workforce as part of a ...

(Reuters) -British biotech firm Redx Pharma plc and U.S.-based Jounce Therapeutics Inc will merge to create a $425 million entity specialised in treating cancer and fibrotic disease. Redx shareholders ...

Jounce Therapeutics (NASDAQ:JNCE) is merging with U.K.-based Redx Pharma in an all stock deal after which the combined company will be known as Redx and listed on Nasdaq under the ticker REDX. The ...

CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and ...

This integration drives app-level supply insights, better campaign control, and outcome-driven automation, all built on a foundation of transparency. Programmatic CTV continues to grow. So do concerns ...

This integration drives app-level supply insights, better campaign control, and outcome-driven automation, all built on a foundation of transparency. MINNEAPOLIS, January 05, 2026--(BUSINESS ...